SBIR-STTR Award

Targeting Exonuclease Resistant Rna to Develop Zika Virus Therapeutics
Award last edited on: 4/30/2018

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$299,236
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Mel Kimsey

Company Information

Nymirum Inc

4324 South Alston Avenue Suite 110
Durham, NC 27713
   (734) 369-4268
   info@nymirum.com
   www.nymirum.com
Location: Single
Congr. District: 01
County: Durham

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2018
Phase I Amount
$299,236
Outbreaks of Zika Virus (ZIKV) have been recorded in Africa, the Americas, Asia, and the Pacific, and despite significant resources being dedicated to combat ZIKV proliferation, there is no known cure. Many mosquito- borne flavivirus such as ZIKV, Dengue virus, Yellow Fever virus, and West Nile virus have structured 3? UTRs. Structured RNA elements in the 3Â’UTRs allow the virus to resist degradation by host exonucleases during infection leading to the production of noncoding subgenomic flavivirus RNAs, which are directly linked to cytopathic and pathologic effects by dysregulating RNA decay pathways and binding cellular proteins important for antiviral response. We aim to develop small molecules that target the ZIKV exonuclease resistant RNA to promote ZIKV genome degradation by host exonucleases and inhibit viral proliferation and infection. Successfully demonstrating that flaviviral exonuclease resistant RNAs can be targeted by small molecules to inhibit viral proliferation and infection has the potential to create an entirely new field of anti-flavivral drug discovery and lead to the development of broad spectrum anti-flaviviral therapeutics.

Public Health Relevance Statement:
Project Narrative Outbreaks of ZIKV have been recorded in Africa, the Americas, Asia, and the Pacific, and despite significant resources being dedicated to combat ZIKV proliferation, there is no known cure. We aim to develop small molecules that target the ZIKV exonuclease resistant RNA to promote ZIKV genome degradation by host exonucleases and inhibit viral proliferation and infection. Successfully demonstrating that flaviviral exonuclease resistant RNAs can be targeted by small molecules to inhibit viral proliferation and infection has the potential to create an entirely new field of anti-flavivral drug discovery and lead to the development of broad spectrum anti-flaviviral therapeutics.

Project Terms:
3' Untranslated Regions; Africa; Algorithms; Americas; Animal Model; Antiviral Agents; Antiviral Response; Asia; base; Binding; Biochemical; Biological Assay; CD69 antigen; Cells; Chemicals; Collection; combat; Computer software; Congenital Abnormality; Culicidae; Data; Data Reporting; Dengue; Dengue Virus; Development; Disease Outbreaks; drug discovery; Drug Targeting; Elements; Endophthalmitis; Exonuclease; experimental study; fetal infection; Flavivirus; Genomics; Human; In Vitro; in vivo; Infection; innovation; insight; Knowledge; Label; Lead; Legal patent; Libraries; Link; Maps; Mediating; Microcephaly; Nonprofit Organizations; novel strategies; Oral; particle; Pathologic; Pathway interactions; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Pregnancy; prevent; Process; Production; Program Development; Property; Proteins; Public Health; Resistance; Resolution; Resources; RNA; RNA Decay; screening; small molecule; Source; Structure; Structure-Activity Relationship; Syndrome; Technology; Testing; Therapeutic; three dimensional structure; Toxic effect; Untranslated Regions; Viral; Viral Genome; viral RNA; virtual; Virus; Virus Diseases; Virus Replication; West Nile virus; Work; X-Ray Crystallography; Yellow Fever; Yellow fever virus; Zika Virus

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----